Bringing a biologic to market—especially complex modalities like Antibody-Drug Conjugates (ADCs)—requires not only significant investment but seamless integration across development and manufacturing. In this session, Samsung Biologics will share insights on navigating the unique challenges of ADC Drug Substance manufacturing, including payload handling, flexible manufacturing set-up, and cross contamination management. The presentation will also highlight how our recent expansions in ADC capabilities are enabling faster timelines, integrated solutions, and greater manufacturing efficiency for global biopharma partners.
What you can expect:
Meet the speaker:
Marc Studer, Senior Director and Head of ADC/mRNA Operations at Samsung Biologics

Marc brings extensive experience in the CDMO industry and has held roles across quality control, process development, and operations. Prior to joining Samsung Biologics, Mr. Studer served as Associate Director at Lonza, overseeing clinical and commercial bioconjugate manufacturing and the design and scale-up of new manufacturing assets. He holds a Master’s degree in Pharmaceutical Biotechnology from Zurich University of Applied Sciences in Switzerland.
Terms & Conditions | Privacy Policy | Contact us at info@hpcimedia.com or + 44 (0) 20717 05858
© HPCi Media Limited | Registered in England No. 6716035 | Studio 227-8, Metal Box Factory, 30 Great Guildford St, London SE1 0HS | VAT GB 939828072